216 related articles for article (PubMed ID: 22260684)
1. Roles of the mammalian target of rapamycin, mTOR, in controlling ribosome biogenesis and protein synthesis.
Iadevaia V; Huo Y; Zhang Z; Foster LJ; Proud CG
Biochem Soc Trans; 2012 Feb; 40(1):168-72. PubMed ID: 22260684
[TBL] [Abstract][Full Text] [Related]
2. Stable isotope-labelling analysis of the impact of inhibition of the mammalian target of rapamycin on protein synthesis.
Huo Y; Iadevaia V; Yao Z; Kelly I; Cosulich S; Guichard S; Foster LJ; Proud CG
Biochem J; 2012 May; 444(1):141-51. PubMed ID: 22428559
[TBL] [Abstract][Full Text] [Related]
3. mTORC1 signaling controls multiple steps in ribosome biogenesis.
Iadevaia V; Liu R; Proud CG
Semin Cell Dev Biol; 2014 Dec; 36():113-20. PubMed ID: 25148809
[TBL] [Abstract][Full Text] [Related]
4. Differing effects of rapamycin and mTOR kinase inhibitors on protein synthesis.
Huo Y; Iadevaia V; Proud CG
Biochem Soc Trans; 2011 Apr; 39(2):446-50. PubMed ID: 21428917
[TBL] [Abstract][Full Text] [Related]
5. mTOR signaling regulates the processing of pre-rRNA in human cells.
Iadevaia V; Zhang Z; Jan E; Proud CG
Nucleic Acids Res; 2012 Mar; 40(6):2527-39. PubMed ID: 22121221
[TBL] [Abstract][Full Text] [Related]
6. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2.
Feldman ME; Apsel B; Uotila A; Loewith R; Knight ZA; Ruggero D; Shokat KM
PLoS Biol; 2009 Feb; 7(2):e38. PubMed ID: 19209957
[TBL] [Abstract][Full Text] [Related]
7. Rapamycin inhibits cytoskeleton reorganization and cell motility by suppressing RhoA expression and activity.
Liu L; Luo Y; Chen L; Shen T; Xu B; Chen W; Zhou H; Han X; Huang S
J Biol Chem; 2010 Dec; 285(49):38362-73. PubMed ID: 20937815
[TBL] [Abstract][Full Text] [Related]
8. Targeting mTOR globally in cancer: thinking beyond rapamycin.
Shor B; Gibbons JJ; Abraham RT; Yu K
Cell Cycle; 2009 Dec; 8(23):3831-7. PubMed ID: 19901542
[TBL] [Abstract][Full Text] [Related]
9. mTOR Ser-2481 autophosphorylation monitors mTORC-specific catalytic activity and clarifies rapamycin mechanism of action.
Soliman GA; Acosta-Jaquez HA; Dunlop EA; Ekim B; Maj NE; Tee AR; Fingar DC
J Biol Chem; 2010 Mar; 285(11):7866-79. PubMed ID: 20022946
[TBL] [Abstract][Full Text] [Related]
10. mTORC1 regulates the efficiency and cellular capacity for protein synthesis.
Proud CG
Biochem Soc Trans; 2013 Aug; 41(4):923-6. PubMed ID: 23863157
[TBL] [Abstract][Full Text] [Related]
11. RhoA modulates signaling through the mechanistic target of rapamycin complex 1 (mTORC1) in mammalian cells.
Gordon BS; Kazi AA; Coleman CS; Dennis MD; Chau V; Jefferson LS; Kimball SR
Cell Signal; 2014 Mar; 26(3):461-7. PubMed ID: 24316235
[TBL] [Abstract][Full Text] [Related]
12. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes.
Jhanwar-Uniyal M; Gillick JL; Neil J; Tobias M; Thwing ZE; Murali R
Adv Biol Regul; 2015 Jan; 57():64-74. PubMed ID: 25442674
[TBL] [Abstract][Full Text] [Related]
13. Growing knowledge of the mTOR signaling network.
Huang K; Fingar DC
Semin Cell Dev Biol; 2014 Dec; 36():79-90. PubMed ID: 25242279
[TBL] [Abstract][Full Text] [Related]
14. Mammalian target of rapamycin: hitting the bull's-eye for neurological disorders.
Chong ZZ; Shang YC; Zhang L; Wang S; Maiese K
Oxid Med Cell Longev; 2010; 3(6):374-91. PubMed ID: 21307646
[TBL] [Abstract][Full Text] [Related]
15. Increased milk protein synthesis in response to exogenous growth hormone is associated with changes in mechanistic (mammalian) target of rapamycin (mTOR)C1-dependent and independent cell signaling.
Sciascia Q; Pacheco D; McCoard SA
J Dairy Sci; 2013 Apr; 96(4):2327-2338. PubMed ID: 23462168
[TBL] [Abstract][Full Text] [Related]
16. cAMP inhibits mammalian target of rapamycin complex-1 and -2 (mTORC1 and 2) by promoting complex dissociation and inhibiting mTOR kinase activity.
Xie J; Ponuwei GA; Moore CE; Willars GB; Tee AR; Herbert TP
Cell Signal; 2011 Dec; 23(12):1927-35. PubMed ID: 21763421
[TBL] [Abstract][Full Text] [Related]
17. The mammalian target of rapamycin regulates cholesterol biosynthetic gene expression and exhibits a rapamycin-resistant transcriptional profile.
Wang BT; Ducker GS; Barczak AJ; Barbeau R; Erle DJ; Shokat KM
Proc Natl Acad Sci U S A; 2011 Sep; 108(37):15201-6. PubMed ID: 21876130
[TBL] [Abstract][Full Text] [Related]
18. A unifying model for mTORC1-mediated regulation of mRNA translation.
Thoreen CC; Chantranupong L; Keys HR; Wang T; Gray NS; Sabatini DM
Nature; 2012 May; 485(7396):109-13. PubMed ID: 22552098
[TBL] [Abstract][Full Text] [Related]
19. Phosphomimetic substitution of heterogeneous nuclear ribonucleoprotein A1 at serine 199 abolishes AKT-dependent internal ribosome entry site-transacting factor (ITAF) function via effects on strand annealing and results in mammalian target of rapamycin complex 1 (mTORC1) inhibitor sensitivity.
Martin J; Masri J; Cloninger C; Holmes B; Artinian N; Funk A; Ruegg T; Anderson L; Bashir T; Bernath A; Lichtenstein A; Gera J
J Biol Chem; 2011 May; 286(18):16402-13. PubMed ID: 21454539
[TBL] [Abstract][Full Text] [Related]
20. Genetic and pharmacologic evidence that mTOR targeting outweighs mTORC1 inhibition as an antimyeloma strategy.
Chen X; Díaz-Rodríguez E; Ocio EM; Paiva B; Mortensen DS; Lopez-Girona A; Chopra R; Miguel JS; Pandiella A
Mol Cancer Ther; 2014 Feb; 13(2):504-16. PubMed ID: 24431075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
